Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia

British Journal of Haematology

Volumn 91, Issue 4, 1995, Pages 838-845

  Engervall, Per ^a   Andersson, Birger ^b   Björkholm, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CALAB Medical Laboratories   (Sweden)

Author keywords

interferon gamma; interleukin 1 receptor antagonist; interleukin 10; interleukin 6; neutropenia; septicaemia; tumour necrosis factor alpha

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; LEUKEMIA; MALE; NEUTROPENIA; PRIORITY JOURNAL; SEPTICEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CYTOKINES; FEMALE; FEVER; HUMAN; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGE; NEUTROPENIA; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TUMOR NECROSIS FACTOR;

EID: 0028879905     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1995.tb05398.x     Document Type: Article

References (33)

1. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome)
2. How gram‐positive organisms cause sepsis
3. Circulating interleukin‐1 and tumor necrosis factor in septic shock and experimental endotoxin fever
4. Endogenous haemopoietic growth factors in neutropenia and infection
5. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia
6. Plasma tumor necrosis factor and mortality in critically septic patients
7. Interleukin 10 (IL‐10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL‐10 produced by monocytes
8. Anticyokine strategies in the treatment of the systemic inflammatory response syndrome
9. Release of tumor necrosis factor by human polymorphonuclear leukocytes
10. Septicemia and shock syndrome due to viridans streptococci: a case‐control study of predisposing factors
11. Trimethoprim‐sulfamethoxazole plus amikacin as first‐line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with haematological disorders
12. Monitoring of endotoxin, interleukin‐6 and C‐reactive protein serum concentrations in neutropenic patients with fever
13. Interleukin‐1 receptor anatagonist circulates in experimental inflammation and in human disease
14. Septic shock: pathogenesis
15. Production of interleukin‐1‐receptor antagonist during experimental endotoxaemia
16. Increased plasma levels of interleukin‐6 in sepsis
17. Interleukin‐6 and its relationship to C‐reactive protein and fever in children with febrile neutropenia
18. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
19. Peripheral blood neutrophil production of interleukin‐1 receptor antagonist and interleukin‐1/3
20. Interleukin‐10 production during septicaemia
21. Plasma tumor necrosis factor in patients with septic shock: mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration
22. Human neutrophils produce high levels of interleukin 1 receptor antagonist in response to granulocyte/macrophage colony‐stimulating factor and tumor necrosis factor
23. Bioactive and inactive forms of tumor necrosis factor‐a in spinal fluid from patients with meningitis
24. Interleukin‐l receptor antagonist reduces mortality from endotoxin shock
25. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with
26. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy
27. Management of fever in patients with cancer and treatment‐induced neutropenia. New
28. Cytokine and acute‐phase reactant levels in serum of children with cancer admitted for fever and neutropenia
29. Role of interferon‐gamma in experimental Gram‐negative sepsis
30. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia
31. Tumour necrosis factor and interleukin‐6 in Candida albicans infection in normal and granulocytopenic mice
32. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways
33. Cytokine mediators of septic infections in the normal and granulocytopenic host